Interstitial lung disease points to consider for clinical trials in systemic sclerosis

Rheumatology (Oxford, England)

Volumn 56, Issue 5, 2017, Pages v27-v32

  Khanna, Dinesh ^a   Seibold, James ^a   Goldin, Jonathan ^a   Tashkin, Donald P ^a   Furst, Daniel E ^a   Wells, Athol ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

interstitial lung disease clinical trials; lung disease; scleroderma

Indexed keywords

CLINICAL TRIAL (TOPIC); COMPLICATION; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMAN; LUNG DISEASES, INTERSTITIAL; MORTALITY; PROCEDURES; SURVIVAL RATE; SYSTEMIC SCLEROSIS;

CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; GLOBAL HEALTH; HUMANS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC; SURVIVAL RATE;

EID: 85031028845     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex203     Document Type: Review

References (0)